191 related articles for article (PubMed ID: 25072363)
1. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
Albano E; Azie N; Roy M; Townsend R; Arrieta A
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
[TBL] [Abstract][Full Text] [Related]
2. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
3. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Yoshikawa K; Nakazawa Y; Katsuyama Y; Hirabayashi K; Saito S; Shigemura T; Tanaka M; Yanagisawa R; Sakashita K; Koike K
Infection; 2014 Aug; 42(4):639-47. PubMed ID: 24567233
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
[TBL] [Abstract][Full Text] [Related]
7. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients.
Lehrnbecher T; Groll AH
Pediatr Blood Cancer; 2010 Aug; 55(2):229-32. PubMed ID: 20583216
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
Hiemenz J; Cagnoni P; Simpson D; Devine S; Chao N; Keirns J; Lau W; Facklam D; Buell D
Antimicrob Agents Chemother; 2005 Apr; 49(4):1331-6. PubMed ID: 15793107
[TBL] [Abstract][Full Text] [Related]
10. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
Krishna G; Vickery D; Ma L; Yu X; Noren C; Power E; Beresford E; Medlock M
J Clin Pharmacol; 2011 Jan; 51(1):84-92. PubMed ID: 20489029
[TBL] [Abstract][Full Text] [Related]
11. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM
Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants.
Kawada M; Fukuoka N; Kondo M; Okazaki K; Kusaka T; Kawada K; Itoh S
Pediatr Infect Dis J; 2009 Sep; 28(9):840-2. PubMed ID: 19636279
[TBL] [Abstract][Full Text] [Related]
13. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Undre NA; Stevenson P; Freire A; Arrieta A
Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation.
Oshima K; Kanda Y; Kako S; Ohno K; Kishino S; Kurokawa M
Transpl Infect Dis; 2013 Jun; 15(3):323-7. PubMed ID: 23578224
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
[TBL] [Abstract][Full Text] [Related]
18. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study.
Kobayashi C; Hanadate T; Niwa T; Hirano Y; Yoshiyasu T; So M; Matsui K
J Infect Chemother; 2015 Jun; 21(6):438-43. PubMed ID: 25749360
[TBL] [Abstract][Full Text] [Related]
20. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
Bochennek K; Balan A; Müller-Scholden L; Becker M; Farowski F; Müller C; Groll AH; Lehrnbecher T
J Antimicrob Chemother; 2015 May; 70(5):1527-30. PubMed ID: 25564562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
